How I treat HIV-associated lymphoma

Kieron Dunleavy and Wyndham H. Wilson

Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892

Address Reprint Requests to: Kieron Dunleavy, M.D., Metabolism Branch, National Cancer Institute, Building 10, Room 4N-115, 9000 Rockville Pike, Bethesda, MD 20892. Email: dunleavk@mail.nih.gov

Running head: How I Treat HIV-associated Lymphoma
ABSTRACT

Over the past ten years, significant progress has been made in understanding HIV-associated lymphomas and improving the prognosis of these diseases. With the advent of combination antiretroviral therapy (CART) and the development of novel therapeutic strategies, most patients with HIV-associated lymphomas are cured. The outcome for the majority of patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) in particular, is excellent, with recent studies supporting the role of rituximab in these diseases. Indeed, in the CART era, the curability of many patients with HIV-associated lymphoma is similar to their HIV negative counterparts. New treatment frontiers need to focus on improving the outcome for patients with advanced immune suppression and for those with adverse tumor biology such as the activated B-cell (ABC) type of DLBCL and the virally driven lymphomas. Future clinical trials need to investigate novel targeted agents alone and in combination with chemotherapy.
INTRODUCTION

Lymphomas are an important complication of human immunodeficiency virus (HIV) infection where they occur with high frequency and are a significant cause of morbidity and mortality. Most of these are aggressive B-cell lymphomas and are histologically heterogeneous, and include lymphomas that are commonly diagnosed in HIV-negative patients as well as others that are primarily associated with HIV infection and occur in patients with severe immunodeficiency. The common HIV-associated lymphomas are diffuse large B-cell lymphoma (DLBCL), which includes primary CNS lymphoma (PCNSL), and Burkitt lymphoma (BL), while primary effusion lymphoma (PEL), plasmablastic lymphoma and classical Hodgkin lymphoma are far less frequent. Other lymphoma subtypes such as follicular lymphoma and peripheral T-cell lymphoma (PTCL) can also be seen but are quite uncommon. Epidemiologically, HIV-positive patients have a 60-200 fold increased incidence of non-Hodgkin lymphoma, the majority of which are DLBCL\(^1\). The reader is referred to the current WHO Classification for further details, where HIV-associated lymphomas are separately classified under ‘Immunodeficiency-associated lymphoproliferative disorders’\(^2\).

Since the introduction of combination antiretroviral therapy (CART) in the mid-1990s, HIV-associated lymphomas have fallen in incidence and improved in outcome, in large part due to better control of HIV replication and improved immune function. The risk of systemic or primary CNS lymphoma in HIV infected persons is closely associated with the CD4 count. In one study, the incidence of systemic lymphoma rose from 15.6 to 253.8 per 10,000 person-years and PCNSL from 2 to 93.9 per 10,000 person years in
patients with a CD4 cell count of > 350 cells/μL compared to patients with < 50 cells/μL, respectively. In addition, since the widespread use of CART, the proportion of patients in lower CD4 strata has fallen significantly, which has been accompanied by a shift in histological subtype away from lymphomas like PCNSL and PEL, that occur in patients with advanced immunodeficiency, toward BL and HL that occur in patients with higher CD4 counts and better immune function. This pathobiological shift in tumor types in the era of CART has important implications for outcome as the subtypes of lymphoma that arise in the setting of high CD4 counts are more favorable.

PATHO BIOLOGY

The pathogenesis of HIV-associated lymphoma involves a complex interplay of biological factors such as chronic antigen stimulation, co-infecting oncogenic viruses, genetic abnormalities and cytokine dysregulation. Most of these lymphomas are of B-cell lineage and harbor clonal rearrangement of immunoglobulin genes. Occasional T-cell lymphomas are observed and would have T-cell receptor gene rearrangements.

Etiology

Chronic antigen stimulation, which is associated with HIV infection, can lead to polyclonal B-cell expansion and likely promotes the emergence of monoclonal B-cells. Recently, circulating free light chains were found to be elevated in patients at increased risk of HIV-associated lymphomas and may represent markers of polyclonal B-cell activation. In the future, they may be useful for the identification of HIV-infected individuals at increased risk for the development of lymphoma.
EBV is the most commonly found oncogenic virus in HIV-associated lymphomas and is present in approximately 40% of cases\(^2\). Nearly all cases of PCNSL and HL harbor EBV as do 80-90% of DLBCL cases with immunoblastic features. Most cases of PEL also harbor EBV in addition to HHV8, which is present in virtually all cases \(^8\). In contrast, EBV is variably present in BL (30-50%) and plasmablastic lymphoma (50%), and usually absent in centroblastic lymphomas\(^9-11\). EBV positive HIV-associated lymphomas frequently express the EBV-encoding transforming antigen latent membrane protein 1 (LMP-1), which activates cellular proliferation through the activation of the nuclear factor kappa B (NF-kappa-B) pathway and may induce \(BCL2\) overexpression, promoting B-cell survival and lymphomagenesis\(^{12-14}\).

**Molecular Genetics**

There are a number of well-defined genetic abnormalities in HIV-associated lymphoma (Table 1). BL is associated with activation of the \(MYC\) gene and when associated with HIV infection, resembles sporadic rather than endemic BL\(^15\). Interestingly, studies have suggested that up to 20% of HIV positive DLBCLs also harbor a \(MYC\) translocation and this raises the question of whether some of these may be biologically closer to Burkitt lymphomas, as recently described in HIV negative patients\(^{16, 17}\). \(BCL6\) mutations are found in 20 percent of centroblastic DLBCL and 60 percent of PEL lymphoma cases\(^{18-20}\). Finally, cytokine and chemokine dysregulation, such as interleukin 6 and 10 are associated with EBV and HHV8 associated lymphomas and likely play an important and permissive role in lymphomagenesis\(^2\).
Though in-depth gene expression profiling (GEP) of HIV-associated lymphomas has not been performed, their molecular profiles are likely to be similar to DLBCL and BL in HIV-negative patients. Early GEP studies in untreated DLBCL identified distinct molecular subtypes with different oncogenic abnormalities. Genes associated with germinal center B-cell (GCB) DLBCL included markers of germinal center differentiation such as CD10 and BCL6, whereas those associated with activated B-cell like (ABC) DLBCL included IRF4/MUM1. A noteworthy feature of ABC DLBCL was the very high expression of BCL2 - ABC DLBCL had over 4-fold higher expression than GCB DLBCL. These results suggested that the GCB and ABC DLBCL subtypes are derived from B cells at different stages of differentiation with GCB DLBCL arising from germinal center B cells and ABC DLBCL from post-germinal center B cells, blocked during plasmacytic differentiation.

Genetic analysis has revealed ABC and GCB DLBCL to be pathogenetically distinct. GCB DLBCL is exclusively associated with two recurrent oncogenic events, the t(14;18) translocation involving the BCL2 gene and the immunoglobulin heavy chain gene and amplification of the c-rel locus on chromosome 2p. They also have amplification of the oncogenic mir-17-92 microRNA cluster, deletion of the tumor suppressor PTEN, and frequent abnormalities of BCL6. ABC DLBCLs have frequent amplification of the oncogene SPIB, deletion of the INK4a/ARF tumor suppressor locus and trisomy 3 and constitutive activation of the NF-kB pathway, in most cases. This has been linked to abnormalities in several upstream proteins, including, CARD11, BCL10 and A20.
to activation of \( \text{IkB} \) kinase and NF-\( \kappa B \)^{27,30}.

BL can be readily distinguished from DLBCL by the high level of expression of MYC target genes, the expression of a subgroup of germinal center B-cell genes and the low level of expression of major-histocompatibility-complex class I genes and NF-\( \kappa B \) target genes\(^{16,17} \). A few small studies that have looked at gene expression profiling of PEL, found its profile to be similar to the non-GCB type of DLBCL and likely of plasmablastic derivation\(^{32,33} \).

**DIAGNOSIS AND EVALUATION**

The most important diagnostic test is an adequate and properly evaluated biopsy; in general excisional biopsies should be performed and core or fine needle aspiration biopsies are generally inadequate. The tissue evaluation should be performed by an experienced hematopathologist. While many of these lymphomas will be histologically similar to those that develop in HIV negative patients, others, such as PEL and plasmablastic lymphoma, and are seen mostly in HIV infected patients.

**Histology**

HIV-associated DLBCL is divided into centroblastic and immunoblastic variants. The centroblastic type is characterized by diffuse sheets of large lymphoid cells with round or oval nuclei and prominent nucleoli. They often express germinal center associated markers such as CD10 and BCL6 and are typically CD20 positive\(^2,15,34 \) (Figure 1). The
immunoblastic variant refers to those cases containing more than 90% immunoblasts and often exhibits features of plasmacytoid differentiation that may confound the distinction from plasmablastic lymphomas\textsuperscript{2, 35, 36}. These tumors are CD10 negative, being of post-germinal center derivation, and frequently positive for \textit{MUM1/IRF4} and CD138/syndecan-1, markers associated with plasma cell derivation\textsuperscript{15}. These tumors have frequent mitoses with high Ki-67/MIB-1 scores\textsuperscript{37}. The centroblastic type represents approximately 25\% of HIV associated lymphomas whereas the immunoblastic type represents around 10\%. In immunoblastic lymphoma, tumor cells may lose CD20 expression due to co-expression of EBV. Markers associated with activation such as CD30, CD38 and CD71 are often expressed in immunoblastic types\textsuperscript{2, 5}.

The neoplastic cells in PEL range in appearance from large immunoblastic to anaplastic large cell lymphoma-type cells. Though this tumor is of B-cell origin, surface B-cell antigens like CD20 and CD79a are not expressed. CD45, CD30, CD38 and CD138 are usually expressed and as discussed earlier are associated with KSHV/HHV-8 and EBV sometimes\textsuperscript{33}. Finally plasmablastic lymphomas, which typically occur in the oral cavity or jaw are usually positive for CD38, CD138 and \textit{MUM1/IRF4} and negative for CD20 and CD45\textsuperscript{36}. EBV is present in greater than 50\% of cases and these tumors appear to have biological overlap with PEL\textsuperscript{33, 38}.

HIV-associated BL is divided into 3 separate entities\textsuperscript{2}: The classical type accounts for approximately 30 percent of all HIV-associated lymphomas and morphologically resembles classic BL encountered in HIV negative patients. BL with plasmacytoid differentiation is characterized by medium–sized cells with abundant cytoplasm and is
much more commonly seen in the setting of immune deficiency. Other cases show
greater nuclear pleomorphism with fewer but more prominent nuclei and in the past these
were referred to as ‘atypical’ BL. All types have very high mitotic rates with expression
of CD19, CD20, CD79a and CD10 and are negative for BCL2. EBV positivity ranges
from 30% in classical BL to 50-70% in BL associated with plasmacytoid differentiaton\(^6\),
\(^9, 39\).

Classical HL in the setting of HIV is mostly the mixed cellularity subtype and EBV is
positive in virtually all cases\(^40\) – interestingly, in the CART era, there has been a
significant increase in nodular sclerosis HL, due to a higher proportion of patients in
higher CD4 strata\(^33, 41\).

Though GEP is not routinely used in the diagnosis of HIV-associated lymphoma, the cell
of origin of DLBCL (GCB or non-GCB) can be reasonably predicted by the expression of
3 surface proteins (CD10, BCL6 and MUM1) on the tumor tissue using
immunohistochemistry (IHC) as described in the Hans algorithm\(^42\). A recent algorithm
from Choi incorporates two additional antibodies specific to germinal center B-cells
(GCET1 and FOXP1) and may improve the predictive accuracy of IHC\(^43\). Though the
cell of origin appears to be an independent predictor of outcome, with the ABC subtype
(non-GCB) having a worse outcome, both subtypes are treated similarly at present.
However, a recent study suggested that bortezomib may improve the outcome of
doxorubicin-based treatment of ABC DLBCL and is being studied\(^44, 45\). One diagnostic
challenge is identifying \textit{MYC}+ DLBCL, because, like BL, these tumors have a poor

outcome with R-CHOP based treatment\textsuperscript{17,46}. Thus, it is prudent to perform cytogenetics or fluorescent in situ hybridization (FISH) for \textit{MYC} translocations.

\textbf{Evaluation}

Patients should have a comprehensive medical history with attention paid to signs and symptoms of lymphoma, and a detailed HIV history including prior opportunistic infections and history of HIV resistance, immune function, HIV viral control and antiretroviral treatment. The physical examination should include a careful assessment of lymph node regions, the liver and spleen. Relevant laboratory studies include a complete blood count, chemistry profile with lactate dehydrogenase (LDH) and uric acid levels, CD4 cell count and HIV viral load. HIV and hepatitis B and C serologies should be assessed. A bone marrow aspirate and biopsy should be performed at initial diagnosis as involvement by lymphoma is found in up to 20\% of cases. Patients with aggressive B-cell lymphomas should have a lumbar puncture for analysis of cerebrospinal fluid by flow cytometry and cytology to check for leptomeningeal lymphoma\textsuperscript{47}.

Imaging studies should include computed tomography (CT) scanning of the chest, abdomen and pelvis. Radiographic evaluation of the head should also be performed preferably by magnetic resonance imaging (MRI). Fluoro-deoxyglucose positron emission tomography (FDG-PET) is useful in HIV-negative aggressive lymphomas but its role in HIV-associated lymphomas is very poorly studied at this point in time. One of the greatest limitations in using PET is that interpretation can be confounded by inflammation from HIV-associated nodal reactive hyperplasia, lipodystrophy and
infections. Prior experience evaluating FDG-PET in HIV-associated lymphoma is limited to small retrospective series where most scans were not predictive of remission.

The International Prognostic Index (IPI) is the standard prognostic assessment tool in HIV-negative DLBCL. Its applicability to HIV-associated DLBCL, however, is controversial. While in some studies using CHOP or R-CHOP, the IPI score has divided groups prognostically, this has not been the case with DA-EPOCH and in a recent study of short course-EPOCH-R (infusional etoposide, vincristine and doxorubicin with prednisone, cyclophosphamide, and rituximab) in newly diagnosed HIV-associated DLBCL, the IPI did not predict PFS or OS. The prognostic importance of CD4 cell count and immune function in HIV-associated DLBCL, neither of which are part of the IPI, are the most likely confounding variables. Patients with CD4 counts less than 100 cells/μl are at increased risk of serious opportunistic infections and death. Furthermore, as noted earlier, patients with severe immune suppression have a higher incidence of immunoblastic subtypes, most of which are of ABC derivation, and a poor outcome compared to patients with preserved immunity, where the GCB subtype is more common. Although a recently reported study from the AIDS Malignancy Consortium (AMC) did not find an association between the cell of origin and outcome in HIV-associated DLBCL, their analysis was retrospective and included patients treated with a variety of different regimens. Involvement of the CNS, which is increased in HIV-associated aggressive B-cell lymphomas, also confers an adverse prognosis.
THERAPEUTIC CONTROVERSIES

The treatment of HIV-associated lymphoma has evolved over the last 30 years in line with improved control of HIV replication and preservation of immune function (Table 2). Over this period, the therapeutic questions were driven by the need to balance the administration of effective cytotoxic treatment with its effect on immune function and infectious complications: 1) should lower doses of chemotherapy be used to reduce toxicity and immune suppression?; 2) what is the role of rituximab and the optimal regimen?; and 3) should CART be suspended during lymphoma therapy?

Dose Intensity

In the pre-CART era, patients with HIV-associated lymphoma had poor outcomes with median survivals of five to six months. Because these outcomes were driven by both chemotherapy failure and infections, investigators have examined the effect of chemotherapy dose on survival. In one study, Kaplan and colleagues observed that higher doses of cyclophosphamide were associated with lower survival, suggesting that infections were a driving cause of death in these patients. In an attempt to reduce infectious deaths, the AIDS Malignancy Consortium (AMC) conducted a study of 192 untreated lymphoma patients randomly assigned to receive standard-dose m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone) with granulocyte macrophage colony-stimulating factor (GM-CSF) support or low-dose mBACOD without GM-CSF in an effort to reduce the toxicity of
chemotherapy\textsuperscript{56}. Compared to full-dose therapy, reduced-dose treatment had a similar response rate (52 percent versus 41 percent, respectively) and median survival (6.8 versus 7.7 months respectively) but lower hematological toxicity. This led the authors to conclude that lower dose chemotherapy was preferable in HIV-associated lymphoma. One shortcoming of the study was that although the authors controlled for the absolute CD4 cell count in the survival analysis, they did not include enough patients with high CD4 counts and ultimately, could not support a definitive recommendation for this group where the benefit of full dose chemotherapy on cure of the lymphoma may outweigh the infectious risks\textsuperscript{37}. In addition, in the post CART era, the proportion of patients with higher CD4 counts is much larger. Importantly, before completion of this trial, a randomized multi-center study in HIV-negative aggressive lymphoma showed CHOP to be equally effective as mBACOD and less toxic\textsuperscript{57}. The better therapeutic index of CHOP led to its acceptance as a standard for HIV-associated lymphoma\textsuperscript{58}.

**Outcome in the CART era and the role of rituximab**

The introduction of CART some 15 years ago has had a dramatic effect on the outcome of HIV-associated lymphomas with increases in median survival. While the reasons are multifactorial, they can be ultimately attributed to salutary effects of CART on immune function. Patients with preserved immune function have a lower risk of infectious complications, thereby enabling optimal chemotherapy administration, and as noted earlier, a more favorable tumor biology\textsuperscript{5, 37}. Interestingly, in one study that looked at risk-adapted intensive chemotherapy in 485 patients with AIDS-related lymphoma
Although the benefit of rituximab is well established in HIV-negative DLBCL, its role in HIV-associated DLBCL has been controversial. This debate stems from an AMC randomized phase III study of CHOP ± rituximab in HIV-associated aggressive lymphomas that found rituximab was associated with significantly more infectious deaths but only a trend in improved tumor control; based on this, the authors concluded that rituximab does not improve the clinical outcome of HIV-associated DLBCL. A retrospective analysis of 3 phase II trials from Italy, where patients received infusional cyclophosphamide, doxorubicin and etoposide (CDE) with rituximab, also concluded that rituximab might increase infections. On closer evaluation of the AMC trial, however, the increased infectious deaths occurred primarily in patients with very low CD4 counts, and many patients received 'maintenance' rituximab after chemotherapy, which has not been shown to be useful in HIV-negative DLBCL. Needless to say, these shortcomings confound any interpretation that rituximab is not useful in HIV-associated DLBCL.

Subsequent to the AMC study, a French group performed a phase II study of CHOP plus rituximab in HIV-associated NHL and the CR rate of 77% and 2 year-survival rate of 75% suggested that rituximab was beneficial and could be given safely to this group of patients. To further address the controversy of rituximab, the AMC performed another randomized phase II study. At the time that this study was designed, the results of the EPOCH regimen in this population were very promising and they randomized patients to
receive concurrent versus sequential rituximab with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and hydroxydaunorubicin)\textsuperscript{37, 52}. Importantly they found that concurrent rituximab was not associated with increased infectious deaths \textsuperscript{37, 52}. The study also examined if the CR rate with EPOCH-R was superior to CHOP ± rituximab, employing a predetermined retrospective analysis, and if concurrent versus sequential rituximab was more toxic and/or more effective. There was no difference in toxicity between the arms and the authors rejected the null hypothesis of 50\% (associated with CHOP ± rituximab) in favor of 75\% CR for EPOCH with concurrent rituximab (p=0.005; power 0.89)\textsuperscript{52}. Based on this study, we consider it very unwise to omit rituximab from upfront therapy in HIV-associated lymphoma.

The results of the aforementioned AMC trial and our own findings with EPOCH-based treatment in HIV-associated lymphomas suggests it may be an optimal treatment regimen\textsuperscript{37, 48}. While one group demonstrated good efficacy with R-CHOP in a multi-center setting, it is concerning that 15\% of enrolled patients were enrolled patients were not evaluable for response due to early events or lacking clinical and radiological evaluations \textsuperscript{64}. Though the AMC’s conclusions regarding EPOCH-R’s superiority over R-CHOP is based on a historical comparison, the dramatic differential outcome with these two regimens in a similar patient population suggests to us that EPOCH-R is a better regimen in this population. Whether or not there are subgroups of patients with HIV-associated DLBCL who may do as well with R-CHOP is unknown at this time and we therefore recommend using EPOCH-R in all patients with HIV-associated lymphoma.
Our current strategy involves a second-generation EPOCH regimen termed Short Course-EPOCH-RR (Figure 2), which is based on the good efficacy and tolerability of DA-EPOCH in this patient population. This approach is designed to address the dual challenge of achieving excellent tumor control while preserving immune integrity. While we previously demonstrated that 6 cycles of DA-EPOCH is highly effective (PFS and OS of 73% and 60% at 53 months) in HIV-associated lymphoma, we hypothesized that the addition of rituximab would enhance efficacy and allow a significant reduction in treatment cycles. With 5 years follow-up, the PFS and OS of SC-EPOCH-RR are 84% and 68%, respectively, and 79% of patients only required 3 treatment cycles. In our study, PFS included patients who relapsed or were refractory or died from lymphoma but HIV related deaths were censored.

To determine how many cycles of SC-EPOCH-RR are needed, we employ the paradigm shown in Figure 3. All patients undergo restaging with CT and FDG-PET scan after the second treatment cycle and each cycle thereafter until achieving a CR or no further tumor shrinkage. The criteria for stopping treatment is when, after a minimum of 3 cycles of therapy, there is < 25% reduction in bi-dimensional products compared to the previous interim CT scan and the standardized uptake values (SUVs) on FDG-PET have decreased by at least 50% compared to the pre-treatment FDG-PET. All patients receive at least 3 cycles of therapy. Our liberal definition of required SUV reduction was necessary to take into account HIV-associated reactive changes that confound FDG-PET interpretation in HIV positive patients.
We also required that all patients receive intrathecal therapy for prophylaxis of CNS lymphoma; patients receive 12 mgs of methotrexate intrathecally on days 1 and 5 of cycle 3 and this is repeated every 3 weeks for a total of 6 doses (i.e. cycle 3-5). If patients have active leptomeningeal disease at diagnosis, detected by cytology or flow cytometry, they receive induction intrathecal or intraventricular methotrexate twice weekly for 2 weeks beyond negative flow cytometry (for a minimum of 4 weeks), followed by consolidation weekly for 6 weeks and maintenance monthly for 6 months\(^47\). All patients also receive prophylaxis for pneumocystis jiroveci and for mycobacterium avium if the CD4 count at lymphoma diagnosis is < 100/μL.

Interestingly, with this approach, the clinical prognostic characteristics that make up the IPI and the IPI itself, do not predict PFS or OS. Only tumor histogenesis is associated with lymphoma-specific outcome with 95% of GCB versus 44% of non-GCB DLBCL progression-free at 5 years. Although, both EBV positivity of the tumor and low CD4 count at diagnosis are significantly associated with an inferior overall survival, they are not associated with lymphoma-specific outcome (Figure 3).

**Role of CART during therapy**

The risks and benefits of continuing CART during curative chemotherapy of aggressive lymphomas have been variably interpreted. While many investigators rightly raise the concern that uncontrolled HIV replication during chemotherapy will worsen immune function, they often do not consider the potentially adverse effects of CART on lymphoma-specific outcomes because they are difficult to quantify. One of the first trials
to assess concurrent CART was a non-randomized AMC study of dose reduced and standard dose CHOP \(^65\). A potentially important finding of the study comes from the pharmacokinetic (PK) analysis which showed that cyclophosphamide clearance was reduced 1.5 fold but doxorubicin clearance was unchanged compared to historical results. While it is reassuring that the doxorubicin PK was unaffected, the reduced clearance of cyclophosphamide – an inactive prodrug – could likely result in a reduction of active metabolites and potentially compromise efficacy. In this study, CD4 counts increased significantly during therapy and the mechanism for increased CD4 cell counts raises the concern that CART protects T-cell cells from chemotherapy-induced cytotoxic stress, an effect that might occur in the lymphoma cells\(^66,67\). While other groups have suggested that CART can be safely administered with chemotherapy, it has not been well prospectively studied and controversies abound\(^68,69\). In that respect, it is important to note that many newer antiretrovirals with fewer drug interactions (than those studied in the past) are now available.

Our approach has been to suspend CART during chemotherapy because we believe the risk-benefit of CART is not favorable. We are particularly concerned with pharmacokinetic and pharmacodynamic interactions that could lead to lower steady state drug concentrations, a particular problem with infusional regimens, and/or increase toxicity, which may lead to chemotherapy dose reductions \(^70,71\). Of theoretical but no less important concern is the potential inhibitory effect of some antiretroviral drug classes on lymphoid cell apoptosis and the potential for CART non-compliance, which would increase the risk of developing new HIV mutations \(^72,73\). To assess the risks of CART
suspension, we performed two prospective studies where CART was suspended during chemotherapy (DA-EPOCH and SC-EPOCH-RR), and did not observe a significant increased risk of infections during therapy\textsuperscript{37, 48}. While the HIV viral loads rapidly increased and then plateaued after the first cycle and the CD4 cells decreased over the course of chemotherapy, both HIV viral loads and CD4 cells returned to levels below pre-treatment levels\textsuperscript{37, 48}. Furthermore, there was loss of HIV-viral mutations, which were present before treatment, following completion of EPOCH. Thus, our current approach with SC-EPOCH-RR is to suspend CART from the beginning until the completion of treatment and as 79\% of patients require just 3 cycles of therapy, the duration of CART suspension is approximately 7 weeks, in the majority of cases (Figure 3).

**HIV-associated Burkitt lymphoma**

Though, following the advent of CART, there was a significant improvement in the outcome of HIV-associated DLBCL, this was not the case initially with HIV-associated Burkitt lymphoma, as reported in a retrospective series by Lim et al\textsuperscript{74}. This lack of improvement is likely explained by the widespread use of CHOP-based regimens, which have poor efficacy in BL\textsuperscript{16, 75}. While dose-intense regimens such as hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone) and CODOX-M-IVAC, with or without rituximab, have shown encouraging results in HIV-negative BL, they have not been studied too extensively in HIV-associated BL. One of the concerns with CODOX-M-IVAC is treatment related toxicity in this population\textsuperscript{76, 77}. 
In an attempt to reduce this, the AMC recently presented the results of a feasibility and toxicity study for HIV-associated BL and atypical BL and reported good overall survival rates with 65% of patients completing treatment as per protocol 78.

Burkitt lymphoma highlights the necessity to balance treatment efficacy and toxicity by optimizing the therapeutic index, especially in patients who are immune suppressed and/or elderly. In this regard, we studied using DA-EPOCH-R in untreated BL based on its excellent activity in highly proliferative DLBCL and its favorable toxicity profile. Among 29 patients (including 10 HIV-positive treated with SC-EPOCH-RR), we observed a complete remission and overall survival rate of 100% at a median follow-up time of 57 months. The AMC also included several patients with BL or Burkitt-like lymphoma in their study of concurrent versus sequential EPOCH-R and reported high response rates in this group 52. In summary, while modified CODOX-M-IVAC regimens are effective and reasonably well tolerated in this population, our current approach is to use SC-EPOCH-RR for newly diagnosed patients with HIV-associated BL (Figure 2). The treatment paradigm that we use is the same as for DLBCL with the majority of patients requiring only 3 cycles of therapy and short duration of CART suspension (Figure 3) 48. All patients receive prophylactic intrathecal therapy and those with leptomeningeal disease at diagnosis receive intensive intrathecal therapy for at least 6 months duration 48. A prospective national study that will test the regimen in both HIV negative and positive patients with BL is planned at this time.

**APPROACHES TO OTHER HIV-ASSOCIATED LYMPHOMAS**
Hodgkin Lymphoma

In the setting of HIV infection, classical HL occurs mostly frequently in patients with depressed immune function. However, a paradoxical increase in cHL has been observed in the CART era despite an overall improvement in immune function in most patients. This is likely explained by examining the incidence of the two major subtypes of cHL that occur in HIV infection. In the pre-CART era, most cHL was mixed cellularity subtype, which is EBV positive and occurs mostly in immune suppressed patients, whereas more recently there has been an increased incidence of nodular sclerosis HL, which occurs more commonly at higher CD4 counts. When considering treatment, one needs to consider that patients with the mixed cellularity subtype typically have advanced disease, including bone marrow involvement, and require chemotherapy alone. In contrast, patients with nodular sclerosis HL will typically present with mediastinal masses, and may benefit from combined modality treatment in selected cases. No studies have adequately evaluated different regimens in HIV-associated HL to make definitive recommendations about regimen efficacy. Thus, we recommend ABVD chemotherapy, which is the standard for HIV-negative patients. The impact of CART suspension has not been well studied in HL, but given the relatively long treatment duration and bolus scheduling of ABVD, we recommend that CART be continued.

Primary Central Nervous System Lymphoma

PCNSL typically presents in patients with severe immune suppression. Thus, it is not unexpected that since the advent of CART, its incidence has decreased dramatically.
While the disease remains incurable in most patients, the duration of survival appears to have increased. Compared to HIV negative patients, HIV-associated PCNSL is typically EBV positive\(^2\). Patients frequently present with changes in mental status or focal neurological symptoms and, unlike HIV-negative PCNSL, they tend to present with multiple brain lesions. Because these patients are severely immune suppressed, intracranial opportunistic infections should always be considered in the differential diagnosis when evaluating intracranial lesions on imaging studies.

Unlike HIV-negative PCNSL, where high-dose methotrexate and, more recently, combination chemotherapy regimens are effective, total brain irradiation remains standard in HIV-associated PCNSL. While most studies in the pre-CART era report a median survival in the range of 3 months, survival over 1.5 years has been reported in patients who respond to CART and were treated with radiation\(^{80, 81}\). The role of systemic therapy and rituximab remains undefined in this disease, although some studies are investigating these agents. Our approach is to recommend that these patients be referred for investigational studies or if unavailable, total brain radiation is reasonable.

**Primary Effusion and Plasmablastic Lymphoma**

The outcome of PEL is poor with standard treatment and the median survival is in the range of 6 months\(^{82}\). Unlike some other HIV-associated lymphomas, CART does not appear to have had a significant impact on survival. At this time, the optimal therapy for PEL remains to be defined but regimens such as EPOCH and CDE may be beneficial. Other approaches such as high dose methotrexate and parenteral zidovudine (AZT) with
interferon alpha have been studied but have demonstrated limited efficacy\textsuperscript{83, 84}. The prognosis of plasmablastic lymphoma in the setting of HIV has also been historically poor\textsuperscript{38, 85}. The impact of CART has not been well studied but anecdotal reports suggest its prognosis may have improved since the introduction of CART\textsuperscript{86}. It is reasonable to consider regimens such as EPOCH or CDE for this disease. Newer agents like bortezomib and lenalidomide have been used anecdotally with some reports of activity and success\textsuperscript{87}.

### RELAPSED LYMPHOMA

Relapsed lymphoma is associated with a poor prognosis and median survivals tend to be less than 1 year. A recent Italian study prospectively evaluated high dose therapy and stem cell transplantation in 50 patients with relapsed HIV-associated lymphoma (both HL and NHL)\textsuperscript{88}. While the median overall survival of patients was 33 months, patients who had chemo-sensitive disease had a relatively favorable outcome and were disease free at 44 months follow-up. Given the significant improvements in HIV control and immune function, it is reasonable to approach relapsed HIV- associated lymphomas similarly to their HIV negative counterparts and to pursue aggressive strategies if appropriate. Less aggressive strategies, such as ESHAP and CDE, have poor outcomes \textsuperscript{62, 89}. The role of allogeneic transplantation has not been well evaluated at this time.
FUTURE DIRECTIONS

In summary, our approach to treating HIV associated DLBCL and BL is to use EPOCH-R (with antiretroviral therapy suspension) and preliminary evidence from our institution suggests that abbreviated cycles may be given to further reduce toxicity. For BL, other approaches like modified CODOX-M-IVAC are also being investigated. For HL, we use ABVD with antiretroviral continuation, due to the long duration of therapy. For PCNSL and less common HIV-associated lymphomas, survival with standard approaches to date has been poor and experimental therapy should be considered.

The outcome of HIV-associated lymphoma has undergone significant improvement in recent years beginning with the widespread use of CART. Both DLBCL and BL are highly curable diseases for the most part. To further improve the outcome of these lymphomas, the challenge is to identify driver pathways and therapeutic targets. In this regard, we are investigating modulation of the B-cell receptor cascade and NFκB transcription factor, which are involved in the pathobiology of ABC DLBCL. For GCB DLBCL and BL, current approaches have excellent efficacy with little room for improvement so that future studies should focus on further reducing treatment toxicity, particularly in highly immune suppressed patients. Advances in the therapeutics of poor prognostic diseases like HIV-associated PCNSL and PEL, that are now much more rarely encountered, will likely come from improved understanding of their pathobiology.
Authorship

KD and WHW were involved in the writing and final approval of the manuscript. The authors have no conflicts of interest to declare.

References


Figure legends

Figure 1. A model for the histogenesis of human immunodeficiency virus (HIV)-associated lymphomas showing molecular and viral pathogenesis, and diffuse large B-cell lymphoma taxonomy

Figure 2. SC-EPOCH-RR – drug doses and schedule SC-EPOCH-RR is administered through a central line. Patients have a CBC twice weekly and at least 3 days apart. Cyclophosphamide is reduced 25% for a nadir absolute neutrophil count (ANC) less than 0.5 x 10^9/L (500/mm^3) or platelet count less than 25.0 x 10^9/L (25000/mm^3) lasting 2 to 4 days and 50% if the nadir ANC was less than 0.5 x 10^9/L (500/mm^3) or platelet count less than 25.0 x 10^9/L (25000/mm^3) lasting for 5 or more days, based on twice weekly blood counts

Figure 3. SC-EPOCH-RR treatment paradigm. Patients receive 2 cycles of SC-EPOCH-RR and are then restaged by CT and FDG-PET scanning. Patients in CR after 2 cycles receive 1 more cycle (minimum 3) of therapy. Patients with a “positive” CT and/or FDG-PET study after 2 cycles receive additional cycles until they were negative, for a maximum of 6 cycles.

Figure 4. PFS and OS Kaplan-Meier curves. PFS (A) is 84% and OS (B) is 68% at the median follow-up of 5 years. PFS (C) and OS (D) for patients with GCB versus non-GCB DLBCL. PFS (E) and OS (F) for EBV-negative versus EBV-positive DLBCL, and PFS
(G) and OS (H) for CD4 cell count greater than 100 cells/µL (100 cells/mm$^3$) versus less than 100 cells/µL (100 cells/mm$^3$) at diagnosis.
Table 1  Viral and genetic abnormalities in human immunodeficiency virus (HIV)- associated lymphomas

<table>
<thead>
<tr>
<th>Histologic subtype</th>
<th>EBV +</th>
<th>KSHV/ HHV-8+</th>
<th>Common recurring chromosomal abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diffuse large B-cell lymphoma</td>
<td>30% 2,10, 11</td>
<td>0</td>
<td>MYC (10%); BCL6 (20% of centroblastic DLBCL) 19, 20</td>
</tr>
<tr>
<td>Centroblastic</td>
<td>80-90% 2, 10,11</td>
<td>0</td>
<td>TP53 (40%) 5, 89</td>
</tr>
<tr>
<td>Immunoblastic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmablastic lymphoma</td>
<td>&gt; 50% 2</td>
<td>80% 82</td>
<td>None</td>
</tr>
<tr>
<td>Primary effusion lymphoma</td>
<td>100% 2, 8</td>
<td>100% 2, 8</td>
<td>None</td>
</tr>
<tr>
<td>Burkitt lymphoma</td>
<td>30-50% 2, 9</td>
<td>0</td>
<td>MYC (100%); TP53 (50-60%) 5, 89</td>
</tr>
<tr>
<td>Primary CNS lymphoma</td>
<td>100% 10</td>
<td>0</td>
<td>BCL6 (30-40%) 2</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>80-100% 2</td>
<td>0</td>
<td>None</td>
</tr>
</tbody>
</table>

EBV, Epstein-Barr virus; KSHV/HHV-8, Kaposi sarcoma herpes virus/human herpes virus 8; CNS, central nervous system.
<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Study design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaplan et al. 54</td>
<td>Prospective multicenter randomized phase III (n=192)</td>
<td>Randomization to standard-dose m-BACOD with GM-CSF versus low-dose m-BACOD without GM-CSF. No cART</td>
<td>Similar efficacy of both regimens but less hematological toxicity with low-dose m-BACOD</td>
</tr>
<tr>
<td>Ratner et al. 63</td>
<td>Prospective multicenter sequential phase II (n=65)</td>
<td>First 40 patients received modified-dose (m) CHOP (50% cyclophosphamide and doxorubicin) and the next 25 patients received standard-dose CHOP. cART was administered</td>
<td>CR higher with full dose CHOP compared to mCHOP (48% vs 30%). Authors concluded that concomitant cART was safe but unable to conclude superiority of one regimen over another</td>
</tr>
<tr>
<td>Sparano et al. 66</td>
<td>Prospective multicenter sequential phase II (n=98)</td>
<td>First 43 patients received didanosine and the next 55 patients received cART with CDE</td>
<td>At 2 years, FFS and OS were 36% and 43%. Patients receiving concomitant cART had better survival and less toxicity</td>
</tr>
<tr>
<td>Mounier et al. 57</td>
<td>Prospective multicenter phase III study</td>
<td>48S patients were randomly assigned to different CHOP-based chemotherapy regimens according to an HIV score that was based on performance status, prior AIDS and CD4 count</td>
<td>Though HIV score, IPI score and cART affected survival, the intensity of CHOP-based chemotherapy had no effect on survival</td>
</tr>
<tr>
<td>Little et al. 37</td>
<td>Prospective single center phase II (n=39)</td>
<td>All patients received EPOCH and G-CSF with cART suspension</td>
<td>CR was 74%. At 53 months, DFS and OS were 92% and 60%. Patients in CR achieved CD4 recovery and HIV control following treatment. Conclusion that EPOCH with cART suspension is feasible and highly effective</td>
</tr>
<tr>
<td>Kaplan et al. 59</td>
<td>Prospective multicenter randomized phase III (n=150)</td>
<td>Randomization (2:1) to R-CHOP versus CHOP with concomitant cART. Some patients received maintenance rituximab.</td>
<td>CR rate higher with R-CHOP compared to CHOP (57.6% vs 47%). Increased infectious deaths with R-CHOP mostly in patients with low CD4 counts. Conclusion that rituximab does not improve clinical outcome</td>
</tr>
<tr>
<td>Boue et al 64</td>
<td>Prospective multicenter phase II (n=61)</td>
<td>All patients received R-CHOP</td>
<td>CR in 77% of patients. Estimated 2 year OS was 75%</td>
</tr>
<tr>
<td>Spina et al. 61</td>
<td>Retrospective analysis of 3 phase II trials</td>
<td>Pooled results from 3 trials of CDE with rituximab</td>
<td>CR rate was 70%. At 2 years, FFS and OS were 59% and 64%. Conclusion that R-CDE is effective but rituximab may increase infections</td>
</tr>
<tr>
<td>Sparano et al. 50</td>
<td>Prospective multicenter phase II study</td>
<td>101 patients were randomized to receive either concurrent or sequential rituximab with DA-EPOCH</td>
<td>There was a superior outcome with concurrent rituximab and DA-EPOCH (CR rate 75%) and this was considerably better when compared to the previous ANC results with CHOP +/- R</td>
</tr>
<tr>
<td>Dunleavy et al. 48</td>
<td>Prospective single center phase II (n=33)</td>
<td>All patients received SC-EPOCH-RR with cART suspension</td>
<td>79% of patients needed only 3 cycles of treatment. At 5 year follow-up, PFS and OS were 84% and 68%. Outcome was better for GCB versus non-GCB DLBCL (5 year PFS of 95% versus 44%).</td>
</tr>
</tbody>
</table>

GM-CSF, granulocyte macrophage colony-stimulating factor; G-CSF, granulocyte colony stimulating factor; cART, combined anti-retroviral therapy; CR, complete remission; FFS, failure-free survival; OS, overall survival; DFS, disease-free survival, m-BACOD, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R, rituximab; CDE. Cyclophosphamide, doxorubicin, and etoposide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; DA, dose adjusted; SC, short-course.
Table 1 A model for the histogenesis of human immunodeficiency virus (HIV)-associated lymphomas showing molecular and viral pathogenesis, and diffuse large B-cell lymphoma taxonomy.

<table>
<thead>
<tr>
<th>Germinal Center</th>
<th>Post-Germinal Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germinal Center B-cell type (GCB)</td>
<td>Post-Germinal Center type (ABC)</td>
</tr>
<tr>
<td>Mild immunodeficiency</td>
<td>Severe immunodeficiency</td>
</tr>
<tr>
<td>Moderate CD4 count</td>
<td>Low CD4 count</td>
</tr>
<tr>
<td>Good Prognosis</td>
<td>Poor prognosis</td>
</tr>
<tr>
<td>Post-CART</td>
<td>Pre-CART</td>
</tr>
</tbody>
</table>

- **Mild immunodeficiency**
  - BL: CD20 +, EBV +/-, MUM1/IRF4 -
  - CD10/BCL6 +
  - DLBCL-CB: CD20 +, EBV -/+ MUM1/IRF4-
  - CD10/BCL6 +
- **Moderate CD4 count**
- **Good Prognosis**
- **Post-CART**

**Post-Germinal Center**

<table>
<thead>
<tr>
<th>Activated B-cell type (ABC)</th>
<th>Plasmacytic type</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD20 +, EBV +/-, MUM1/IRF4 -</td>
<td></td>
</tr>
<tr>
<td>CD10/BCL6 +</td>
<td></td>
</tr>
<tr>
<td>CD20 +, EBV ++/-, MUM1/IRF4 +</td>
<td>Severe immunodeficiency</td>
</tr>
<tr>
<td>CD10/BCL6 -</td>
<td></td>
</tr>
<tr>
<td>CD20 -, EBV +, KSHV/HHV8 +</td>
<td>Low CD4 count</td>
</tr>
<tr>
<td>MUM1/IRF4 -</td>
<td></td>
</tr>
<tr>
<td>CD10/BCL6 -</td>
<td></td>
</tr>
<tr>
<td>CD20 -, EBV +, KSHV/HHV8 +</td>
<td>Poor prognosis</td>
</tr>
<tr>
<td>MUM1/IRF4 -</td>
<td></td>
</tr>
<tr>
<td>CD10/BCL6 -</td>
<td></td>
</tr>
<tr>
<td>CD20 -</td>
<td></td>
</tr>
<tr>
<td>EBV +</td>
<td></td>
</tr>
<tr>
<td>KSHV/HHV8 +</td>
<td></td>
</tr>
<tr>
<td>MUM1/IRF4 -</td>
<td></td>
</tr>
<tr>
<td>CD10/BCL6 -</td>
<td></td>
</tr>
<tr>
<td>PB: CD20 -</td>
<td></td>
</tr>
<tr>
<td>EBV +</td>
<td></td>
</tr>
<tr>
<td>KSHV/HHV8 +</td>
<td></td>
</tr>
<tr>
<td>MUM1/IRF4 -</td>
<td></td>
</tr>
<tr>
<td>CD10/BCL6 -</td>
<td></td>
</tr>
</tbody>
</table>

BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; CB, centroblastic; IB, immunoblastic; PEL, primary effusion lymphoma; PB, plasmablastic lymphoma.

Figure 1 A model for the histogenesis of human immunodeficiency virus (HIV)-associated lymphomas showing molecular and viral pathogenesis, and diffuse large B-cell lymphoma taxonomy.
<table>
<thead>
<tr>
<th>Panel</th>
<th>SC-EPOCH-RR – drug doses and schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Dose</strong> mg/m²/day</td>
</tr>
<tr>
<td><strong>Infusional Agents</strong></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>50</td>
</tr>
<tr>
<td>Vincristine</td>
<td>0.4</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>10</td>
</tr>
<tr>
<td><strong>Bolus Agents</strong></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>750</td>
</tr>
<tr>
<td>Prednisone</td>
<td>od=once daily</td>
</tr>
<tr>
<td><strong>Biologic Agents</strong></td>
<td></td>
</tr>
<tr>
<td>G-CSF</td>
<td>300 mcg</td>
</tr>
<tr>
<td>Rituximab</td>
<td>375</td>
</tr>
</tbody>
</table>

Cycle 21 days
Figure 3  SC-EPOCH-RR treatment paradigm

DLBCL or BL

SC-EPOCH-RR x 2

CT/FDG-PET

CR

SC-EPOCH-RR x 1

PR

Routine follow-up

SC-EPOCH-R x 2-4 (1 past CR)

No CART

IT Prophylaxis
MTX 12mg IT on days 1 and 5 of cycles 3-5 (6 doses total) (see text for treatment of lymphomatous meningitis)

*Therapy is stopped when:
1) There is < 25% reduction in bi-dimensional products compared to previous interim CT scan
2) SUV on PET have decreased > 50% compared to the pre-treatment PET

Resume CART

Therapy cessation*
Figure 4  SC-EPOCH-RR in HIV-associated DLBCL: PFS and OS Kaplan Meier curves
How I treat HIV-associated lymphoma

Kieron Dunleavy and Wyndham H. Wilson

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.